IP Library Patent Application 17747938
Patent Application
App. No. 17/747,938

POLYMERIC EMULSION DELIVERY SYSTEMS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/747,938
Abstract

Provided herein are compositions comprising an oil-in-water emulsion, wherein the emulsion comprises a liquid oil component; a cross-linked homopolymer based on acrylic acid and/or a cross-linked copolymer of acrylic acid and acrylic acid esters; and water. In some embodiments, the composition is a vehicle for the delivery of an active agent.

Claims (47)

1 . A topical composition comprising:

a liquid oil component;

a cross-linked homopolymer based on acrylic acid as a first emulsifier, and

water;

wherein the composition forms a stable oil-in-water emulsion.

2 . The topical composition of claim 1 , wherein the liquid oil component is present in an amount of about 30% or less by weight of the composition.

3 . The topical composition of claim 2 , wherein the liquid oil component is present in an amount of about 20% or less by weight of the composition.

4 . The topical composition of any of claims 1 to 3 , wherein the first emulsifer is present in an amount of about 0.01-5% by weight of the composition.

5 . The topical composition of claim 4 , wherein the first emulsifier is present in an amount of about 0.01-3% by weight of the composition.

6 . The topical composition of any of claims 1 to 5 , wherein the ratio of the amount of the liquid oil component to that of the first emulsifer is in the range of about 1:1 to about 28:1.

7 . The topical composition of claim 6 , wherein the ratio of the amount of the liquid oil component to that of the first emulsifer is in the range of about 1:1 to about 20:1.

8 . The topical composition of claim 6 or 7 , wherein the ratio of the amount of the liquid oil component to that of the first emulsifier is in the range of about 3:1 to about 10:1.

9 . The topical composition of any of claims 1 to 8 , wherein first emulsifer is a carbomer homopolymer type A and/or a carbomer homopolymer type C.

10 . The topical composition of any of claims 1 to 9 , wherein the liquid oil component comprises mineral oil, light mineral oil, a fatty alcohol, a monocarboxylic acid ester, a dicarboxylic acid ester, a medium chain triglyceride, a long chain triglyceride, or a combination thereof.

11 . The topical composition of any of claims 1 to 10 , wherein the composition further comprises a surfactant or a cross-linked copolymer of acrylic acid and acrylic acid esters as a second emulsifier.

12 . The topical composition of claim 11 , wherein the second emulsifier is a cross-linked copolymer of acrylic acid and acrylic acid esters, present in an amount of about 0.01-3% by weight of the composition.

13 . The topical composition of claim 11 or 12 , wherein the second emulsifer is a carbomer copolymer type B and/or a carbomer copolymer type A.

14 . The topical composition of claim 11 , wherein the composition further comprises a nonionic, anionic, or cationic surfactant in an amount up to about 0.5% by weight of the composition.

15 . The topical composition of claim 14 , wherein the nonionic surfactant is selected from the group consisting of sorbitan esters, polyoxyethytene derivatives of a sorbitan ester, glyceryl monostearate, polyoxyethylene monooleate, polyoxyethylene monostearate and polyoxyethylene monolaurate.

16 . The topical composition of claim 14 , wherein the anionic surfactant is selected from the group consisting of an alkali soap, an amine soap, and a detergent.

17 . The topical composition of claim 14 , wherein the cationic surfactant is selected from the group consisting of quaternium ammonium salts and quaternary amine salts.

18 . The topical composition of any of claims 1 to 10 , wherein the composition does not comprise a second emulsifier.

19 . The topical composition of any of claims 1 to 18 , wherein the oil-in-water emulsion is stable for at least 24 hours at 40° C.

20 . The topical composition of any of claims 1 to 19 , further comprising an active agent.

21 . The topical composition of claim 20 , comprising two or more active agents.

22 . A topical composition, wherein the composition comprises an oil-in-water emulsion, wherein the emulsion comprises:

a liquid oil component, wherein the liquid oil component is in an amount of about 30% or less by weight of the composition;

a polymer selected from the group consisting of a cross-linked homopolymer based on acrylic acid in an amount of about 0.01-5% by weight of the composition, a cross-linked copolymer of acrylic acid and acrylic acid esters in an amount of about 0.01-5% by weight of the composition, and combinations thereof; and

water.

23 . The topical composition of claim 22 , wherein the liquid oil component is present in an amount of about 20% or less by weight of the composition.

24 . The topical composition of claim 22 or 23 , wherein the composition comprises a cross-linked homopolymer based on acrylic acid in an amount of about 0.01-3% by weight of the composition.

25 . The topical composition of claim 22 or 23 , wherein the composition comprises a cross-linked copolymer of acrylic acid and acrylic acid esters in an amount of about 0.01-3% by weight of the composition.

26 . The topical composition of any of claims 22 to 25 , wherein the ratio of the amount of the liquid oil component to that of the polymer is in the range of about 1:1 to about 28:1.

27 . The topical composition of claim 26 , wherein the ratio of the amount of the liquid oil component to that of the polymer is in the range of about 1:1 to about 20:1.

28 . The topical composition of claim 26 or 27 , wherein the ratio of the amount of the liquid oil component to that of the polymer is in the range of about 3:1 to about 10:1.

29 . The topical composition of any of claims 22 to 28 , wherein the liquid oil component comprises mineral oil, light mineral oil, a fatty alcohol, a monocarboxylic acid ester, a dicarboxylic acid ester, a medium chain triglyceride, a long chain triglyceride, or a combination thereof.

30 . The topical composition of any of claims 22 , 23 , or 26 to 29 , wherein the polymer is a cross-linked homopolymer based on acrylic acid.

31 . The topical composition of claim 30 , wherein the cross-linked homopolymer based on acrylic acid is a carbomer homopolymer type A, a carbomer homopolymer type B, or a carbomer homopolymer type C.

32 . The topical composition of claim 31 , wherein the carbomer homopolymer is a carbomer homopolymer type A.

33 . The topical composition of any of claims 22 , 23 , or 26 to 29 , wherein the polymer is a cross-linked copolymer of acrylic acid and acrylic acid esters.

34 . The topical composition of claim 33 , wherein the cross-linked copolymer of acrylic acid and acrylic acid esters is a carbomer copolymer type B and/or a carbomer copolymer type A.

35 . The topical composition of any of claims 22 , 23 , or 26 to 29 , wherein the polymer is a combination of a cross-linked homopolymer based on acrylic acid and a cross-linked copolymer of acrylic acid and acrylic acid esters.

36 . The topical composition of claim 35 , wherein the polymer is a combination of a carbomer homopolymer type A and a carbomer copolymer type B.

37 . The topical composition of claim 35 , wherein the ratio of the amount of the cross-linked homopolymer based on acrylic acid to that of the cross-linked copolymer of acrylic acid and acrylic acid esters is in the range of 0.1:1 to about 100:1.

38 . The topical composition of claim 37 , wherein the ratio of the amount of the cross-linked homopolymer based on acrylic acid to that of the cross-linked copolymer of acrylic acid and acrylic acid esters is in the range of 1.6:1 to about 100:1.

39 . The topical composition of any of claims 22 to 37 , further comprising an active agent.

40 . The topical composition of claim 39 , comprising two or more active agents.

Assignments (12)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Sep 16, 2022
From: BAUSCH HEALTH IRELAND LIMITED; SANTARUS, INC.; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 061122/0879 →
SECURITY INTEREST Recorded Sep 16, 2022
From: BAUSCH HEALTH IRELAND LIMITED; SANTARUS, INC.; SOLTA MEDICAL IRELAND LIMITED
To: BARCLAYS BANK PLC
Reel/Frame 061122/0855 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2022
From: ANGEL, ARTURO; HERMES, CHANDELLE
To: DOW PHARMACEUTICAL SCIENCES, INC.
Reel/Frame 059957/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2022
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 060120/0124 →